FAS and carcinoma: The expression of FAS increases gradually from endometrial hyperplasia to carcinoma, and inhibition of FAS activity by siRNA downregulates E2-stimulated ERα expression and inhibits cell viability in EC cells, indicating that FAS is associated with carcinogenesis of EC and may be a potential therapeutic target for EC (11, 12).